118156-93-7Relevant articles and documents
(E) and (Z)-3-styrylpiperidines as sigma ligands
Mantegani, Sergio,Brambilla, Enzo,Cremonesi, Paolo,Caccia, Carla,Fornaretto, Maria Gioia,Carfagna, Nicola,Colombo, Monica,McArthur, Robert A.,Varasi, Mario
, p. 1525 - 1530 (1997)
A class of (E) and Q-3-styrylpiperidine derivatives was prepared as racemates and evaluated for affinity at σ binding sites labeled with [3H]-(±-SKF-10,047. Some of these compounds exhibited high affinity and selectivity for σ verus D1 and D2 binding sites.
Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia
Zhang, Dongfeng,Li, Peng,Gao, Yongxin,Song, Yaoyao,Zhu, Yaqin,Su, Hong,Yang, Beibei,Li, Li,Li, Gang,Gong, Ningbo,Lu, Yang,Shao, Huanjie,Yu, Chunrong,Huang, Haihong
, p. 7434 - 7452 (2021/06/25)
BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.
A kind of protease inhibitor and its preparation and use
-
Paragraph 0027-0029, (2018/03/25)
The invention discloses a kind of protease inhibitors, and preparation method and application thereof. The invention discloses a kind of compounds and pharmaceutical compositions thereof, and a preparation method and application thereof. The invention relates to a kind of compounds capable of reducing or inhibiting activity of dual leucine zipper kinase in cells or a subject, and application of the compounds, or solvates, hydrates or medicinal salts thereof to prevent or treat patient diseases or related diseases caused by abnormity of dual leucine zipper kinase.